Discontinuation of antiretroviral therapy in patients with chronic HIV infection: Clinical, virologic, and immunologic consequences

AIDS Patient Care and STDs

Volumn 19, Issue 9, 2005, Pages 550-562

  Mata, Rosario C ^a   Viciana, Pompeyo ^a   De Alarcón, Aréstides ^a   López Cortés, Luis F ^a   Gómez Vera, Josefa ^a   Trastoy, Mónica ^a   Cisneros, José M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; CONVALESCENCE; DRUG RESISTANCE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMMUNE RECONSTITUTION; IMMUNOCOMPETENCE; LACTIC ACIDEMIA; LEUKOPLAKIA; LIPOATROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PLANNED TREATMENT INTERRUPTION; PROGNOSIS; REBOUND; RETREATMENT; SIDE EFFECT; T LYMPHOCYTE; THRUSH; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS LOAD;

ADULT; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; MALE; PROGNOSIS; TIME FACTORS;

EID: 25144473488     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2005.19.550     Document Type: Article

References (47)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency. N Engl J Med 1998;338:853-860.
2. Ledergeber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA 1999;282:2220-2226.
3. Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001;285:1308-1315.
4. Viani RM, Araneta MR, Deville JG, Spector SA. Decrease in hospitalisation and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004;39:725-731.
5. Furtado MR, Calaway DS, Phair JO, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
6. Zhang L, Ramratnam B, Tenner-Racz, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
7. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999;100:700-705.
8. DHHS. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. www.AIDsinfo.nih.gov (Last accessed October 29, 2004).
9. Dybul M, Chun T, Yoder C, et al. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters. Proc Natl Acad Sci USA 2001;98:15161-15166.
10. Dybul M, Nies-Kraske E, Dewar R, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 2004;189:1974-1982.
11. Cardiello PG, Hassink E, Ananworanich J, et al. A prospective, randomised trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis 2005;40:594-600.
12. Ananworanich J, Nuesh R, Le Braz M, et al. Failures of 1 week on antiretroviral therapies in a randomized trial. AIDS 2003;17:F33-F37.
13. Fisher M, Hafner R, Schneider C, et al. HIV RNA in plasma rebounds within days during structured tratment interruptions. AIDS 2003;17:195-199.
14. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
15. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
16. Chen R, Westfall A, Cloud G, et al. Long-term survival after initiation of antiretroviral therapy [Abstract 341]. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001.
17. Sterling TR, Chaisson RE, and Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001;15:2251-2257.
18. Egger M. May M, Chene G, et al. Prognosis of HIV-1 infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:110-129.
19. 6/l. AIDS 2003;16:1371-1381.
20. Ruiz L, Carcelain G, Martínez-Picado J, et al. HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F10-F27.
21. García F, Plana M, Ortiz GM, et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2001;15:F29-F40.
22. Ortiz GM, Wellons M, Brancato J, et al. Structured antiretroviral treatment interruptions in chronically HIV-1 infected subjects. Proc Natl Acad Sci USA 2001;98:13288-13293.
23. Lisziewicz J, Rosemberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340:1683-1684.
24. Daar ES, Bai J, Hausner MA, Majchrowicz M, Tamaddon M, Giorgi JV. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998;128:827-829.
25. Lori F, Maserati R, Foli A, Seminari E, Timpone J, Lisziewicz J. Structured treatment interruptions to control HIV. Lancet 2000;355:287-288.
26. Rosemberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-526.
27. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186:634-643.
28. Oxenius A, Price DA, Günthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Nat Acad Sci USA 2002;99:13747-13752.
29. Fagard C, Oxenius S, Günthard H, et al. A prospective trial of structured interruptions in human immunodeficiency virus infection. Arch Intern Med 2003;163:1220-1226.
30. Miller V, Sabin C, Hertogs K, et al. Virological and immunological effects of treatment interruptions in HIV-infected patients with treatment failure. AIDS 2000;14:2857-2867.
31. Devereux HL, Youle M, Johnson MA, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-F127.
32. Izopet J, Massip P, Souyris C, et al. Shift in HIV resistance genotype after treatment interruption and shirt-term antiviral effect following a new salvage regimen. AIDS 2000;14:2247-2255.
33. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuatuing combination antiretroviral drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001;344:472-480.
34. Lawrence J, Mayers D, Hullsick KH et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003;349:837-846.
35. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruptions: Risk factors and clinical sequelae. AIDS 2003;17:126-128.
36. Mussini C, Bugarini, Perno CF, et al. Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/ul. AIDS 2002;16:1551-1559.
37. Skiest DJ, Morrow P, Allen B, McKinsey J, et al. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cell counts/μl. J Acquir Immnune Defic Syndr 2004;37:1351-1357.
38. Taffé P, Rikenbach M, Hirschel B, et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: Results from a cohort study. AIDS 2002;16:747-755.
39. Neumann AU, Tubiana R, Calvez V, et al. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. AIDS 1999;13:677-683.
40. Hatano H, Vogel S, Yoder C, et al. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 2000;14:1357-1363.
41. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003;37:1541-1548.
42. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial. AIDS 2004;18:439-446.
43. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV-infected patients in Switzerland: A prospective multicentre study. BMJ 1997;315:1194-1199.
44. Zala C, Salomon H, Ochoa C, et al. Supervised treatment interruption (STI) following d4T/ddI/nevirapine initiated within 6 months of HIV seroconversion [Abstract]. First IAS Conference on HIV Pathogenesis. Buenos Aires, Argentina, July 8-11, 2001.
45. Tremblay CL, Hicks JL, Sutton L, et al. Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection. AIDS 2003;17:1086-1089.
46. Martínez-Picado J, Morales-Lopetegui K, Wrin T, et al. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions. AIDS 2002;16:895-899.
47. Metzner KJ, Boenhoeffer S, Fischer M, et al. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruotions. J Infect Dis 2003;188:1433-1443.